Tiia A. Turunen

Dr. Tiia A. Turunen


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2023 in Genes
Verified
Journal Article
Open access
PDF file
MEMasoumeh Eshaghi
Masoumeh Eshaghi
ONOlga Neustroeva
Olga Neustroeva
ICIftekhar Mahmud Chowdhury
Iftekhar Mahmud Chowdhury
PLPia Laitinen
Pia Laitinen
MVMari-Anna Väänänen
Mari-Anna Väänänen
TTTiia A. Turunen
Tiia A. Turunen
Extracellular vesicles (EVs) naturally carry cargo from producer cells, such as RNA and protein, and can transfer these messengers to other cells and tissue. This ability provides an interesting opportunity for using EVs as delivery vehicles for therapeutic agents, such as for gene therapy. However, endogenous loading of cargo, such as microRNAs (miRNAs), is not very efficient as the copy number of miRNAs per EV is quite low. Therefore, new methods and tools to enhance the loading of small RNAs is required. In the current study, we developed fusion protein of EV membrane protein CD9 and RNA-binding protein AGO2 (hCD9.hAGO2). We show that the EVs engineered with hCD9.hAGO2 contain significantly higher levels of miRNA or shRNA (miR-466c or shRNA-451, respectively) compared to EVs that are isolated from cells that only overexpress the desired miRNA or shRNA. These hCD9.hAGO2 engineered EVs also transfer their RNA cargo to recipient cells more efficiently. We were not able to detect changes in gene expression levels in recipient cells after the EV treatments, but we show that the cell viability of HUVECs was increased after hCD9.hAGO2 EV treatments. This technical study characterizes the hCD9.hAGO2 fusion protein for the future development of enhanced RNA loading to EVs.

3 June 2022
Verified
Book Chapter
Closed access
PDF file
PLPia Laitinen
Pia Laitinen
TTTiia A. Turunen
Tiia A. Turunen
Mikko TurunenMikko Turunen
Mikko Turunen